3.9 Article

White matter and its relationship with cognition in subjective cognitive decline

Publisher

WILEY
DOI: 10.1016/j.dadm.2018.10.008

Keywords

Subjective cognitive decline; Diffusion tensor imaging; Executive function; Memory; Alzheimer's disease

Funding

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  2. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  3. National Institute on Aging
  4. National Institute of Biomedical Imaging and Bioengineering
  5. Alzheimer's Association
  6. Alzheimer's Drug Discovery Foundation
  7. Araclon Biotech
  8. BioClinica, Inc.
  9. Biogen
  10. Bristol-Myers Squibb Company
  11. CereSpir, Inc.
  12. Cogstate
  13. Eisai Inc.
  14. Elan Pharmaceuticals, Inc.
  15. Eli Lilly and Company
  16. EuroImmun
  17. F. Hoffmann-La Roche Ltd.
  18. Genentech, Inc.
  19. Fujirebio
  20. GE Healthcare
  21. IXICO Ltd.
  22. Janssen Alzheimer Immunotherapy Research & Development, LLC
  23. Johnson & Johnson Pharmaceutical Research & Development LLC
  24. Lumosity
  25. Lundbeck
  26. Merck Co., Inc.
  27. Meso Scale Diagnostics, LLC
  28. NeuroRx Research
  29. Neurotrack Technologies
  30. Novartis Pharmaceuticals Corporation
  31. Pfizer Inc.
  32. Piramal Imaging
  33. Servier
  34. Takeda Pharmaceutical Company
  35. Transition Therapeutics
  36. Canadian Institutes of Health Research
  37. AbbVie

Ask authors/readers for more resources

Introduction: Subjective cognitive decline (SCD) is the earliest stage on the continuum toward Alzheimer's disease. This study examined (1) differences in white matter integrity between individuals with SCD and healthy control subjects and (2) how white matter integrity related to memory and executive function. Methods: Diffusion tensor imaging and neuropsychological assessment data were retrieved from the Alzheimer's Disease Neuroimaging Initiative database for 30 individuals with SCD and 44 control subjects. Results: Results revealed significantly lower white matter integrity in individuals with SCD relative to control subjects in widespread regions, including the bilateral corticospinal tracts, superior and inferior longitudinal fasciculi, fronto-occipital fasciculi, corpus callosum, forceps major and minor, hippocampi, anterior thalamic radiations, and the cerebellum. There was a widespread relationship between diffusion tensor imaging metrics and executive function in SCD, but not healthy control subjects, and no relationship with memory for either group. Discussion: Relatively lower white matter integrity in SCD may be a useful early biomarker for risk of future cognitive decline. Future research should better characterize the SCD group longitudinally and in individuals at risk for Alzheimer's disease. (C) 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available